Article

Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease.

Center for Stem Cell Biology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA.
Nature (Impact Factor: 42.35). 11/2011; 480(7378):547-51. DOI: 10.1038/nature10648
Source: PubMed

ABSTRACT Human pluripotent stem cells (PSCs) are a promising source of cells for applications in regenerative medicine. Directed differentiation of PSCs into specialized cells such as spinal motoneurons or midbrain dopamine (DA) neurons has been achieved. However, the effective use of PSCs for cell therapy has lagged behind. Whereas mouse PSC-derived DA neurons have shown efficacy in models of Parkinson's disease, DA neurons from human PSCs generally show poor in vivo performance. There are also considerable safety concerns for PSCs related to their potential for teratoma formation or neural overgrowth. Here we present a novel floor-plate-based strategy for the derivation of human DA neurons that efficiently engraft in vivo, suggesting that past failures were due to incomplete specification rather than a specific vulnerability of the cells. Midbrain floor-plate precursors are derived from PSCs 11 days after exposure to small molecule activators of sonic hedgehog (SHH) and canonical WNT signalling. Engraftable midbrain DA neurons are obtained by day 25 and can be maintained in vitro for several months. Extensive molecular profiling, biochemical and electrophysiological data define developmental progression and confirm identity of PSC-derived midbrain DA neurons. In vivo survival and function is demonstrated in Parkinson's disease models using three host species. Long-term engraftment in 6-hydroxy-dopamine-lesioned mice and rats demonstrates robust survival of midbrain DA neurons derived from human embryonic stem (ES) cells, complete restoration of amphetamine-induced rotation behaviour and improvements in tests of forelimb use and akinesia. Finally, scalability is demonstrated by transplantation into parkinsonian monkeys. Excellent DA neuron survival, function and lack of neural overgrowth in the three animal models indicate promise for the development of cell-based therapies in Parkinson's disease.

Download full-text

Full-text

Available from: M. Flint Beal, Jun 20, 2015
0 Followers
 · 
410 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Decisions about what experimental therapies are advanced to clinical trials are based almost exclusively on findings in preclinical animal studies. Over the past 30 years, animal models have forecast the success of hundreds of neuroprotective pharmacological therapies for stroke, Alzheimer׳s disease, spinal cord injury, traumatic brain injury and amyotrophic lateral sclerosis. Yet almost without exception, all have failed. Rapid advances in stem cell technologies have raised new hopes that these neurological diseases may one day be treatable. Still, how can neuroregenerative therapies be translated into clinical realities if available animal models are such poor surrogates of human disease? To address this question we discuss human and rodent neurogenesis, evaluate mechanisms of action for cellular therapies and describe progress in translating neuroregeneration to date. We conclude that not only are appropriate animal models critical to the development of safe and effective therapies, but that the multiple mechanisms of stem cell-mediated therapies may be particularly well suited to the mechanistically diverse nature of central nervous system diseases in mice and man. Copyright © 2015. Published by Elsevier B.V.
    European journal of pharmacology 03/2015; 759. DOI:10.1016/j.ejphar.2015.03.041 · 2.68 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent advances in the generation, propagation, and differentiation of pluripotent stem cells (PSCs) offer great promise in the field of regenerative medicine. Both embryonic stem cells (ESCs) and induced PSCs (iPSCs) provide limitless sources of self-renewing cells endowed with the potential to generate tissue-specific cell populations that can be used in transplantation therapy (Grabel, 2012 and Keller, 2005). However, one major hurdle in realizing this potential is the lack of specific and efficient protocols for differentiating these PSCs to specific populations that can be used for therapeutic applications. Although stem-cell-based regenerative medicine is still a distant goal, outstanding progress has been made in generating and engrafting ESC-derived lineages such as dopamine neurones (Kriks et al., 2011) and cardiomyocytes (Shiba et al., 2012 and Yang et al., 2008). In contrast, since the first report of blood cell generation from ESCs 30 years ago (Doetschman et al., 1985), progress in deriving hematopoietic cells that are able to engraft in vivo has been rather modest. To date, the most successful in vitro derivation of hematopoietic cells capable of repopulating mouse models has relied on the ectopic expression of transcription factors such as HOXB4 (Kyba et al., 2002), CDX4 (Wang et al., 2005b), LHX2 (Kitajima et al., 2011), and RUNX1a (Ran et al., 2013). However, although HOXB4 overexpression has been shown to confer reproducible engraftment capability in differentiating mouse ESCs (Bonde et al., 2008, Kyba et al., 2002, Lesinski et al., 2012 and Matsumoto et al., 2009), this approach has not been successfully translated to human ESCs (Wang et al., 2005a). An alternative approach to the use of HOXB4 in differentiated human ESCs was recently reported by Doulatov et al. (2013), who showed that the ectopic expression of transcription factors (HOXA9, ERG, RORA, SOX4, and MYB) in differentiating ESCs promotes short-term erythroid and myeloid engraftment. Few reports have documented the in vitro generation of hematopoietic repopulating potential from unmanipulated ESCs (Burt et al., 2004, Hole et al., 1996, Müller and Dzierzak, 1993 and Potocnik et al., 1997). However, these approaches have not been reproduced or pursued, suggesting that they involve serum-dependent conditions that cannot be easily replicated. The use of high serum concentrations (Wang et al., 2005a) and/or stroma cell lines (Ledran et al., 2008) to support the formation of repopulating hematopoietic cells derived from human ESCs has also shown promising results, but to date, no follow-up studies have further validated or extended these differentiation protocols. It is likely that the reported successes in deriving repopulating hematopoietic cells relied on specific factors present in rare batches of serum—parameters that are impossible to control for and thus are extremely difficult to reproduce.
    Stem Cell Reports 02/2015; 464(3). DOI:10.1016/j.stemcr.2015.01.003
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Schizophrenia (SZ) is a devastating mental disorder afflicting 1% of the population. Recent genome-wide association studies (GWASs) of SZ have identified >100 risk loci. However, the causal variants/genes and the causal mechanisms remain largely unknown, which hinders the translation of GWAS findings into disease biology and drug targets. Most risk variants are noncoding, thus likely regulate gene expression. A major mechanism of transcriptional regulation is chromatin remodeling, and open chromatin is a versatile predictor of regulatory sequences. MicroRNA-mediated post-transcriptional regulation plays an important role in SZ pathogenesis. Neurons differentiated from patient-specific induced pluripotent stem cells (iPSCs) provide an experimental model to characterize the genetic perturbation of regulatory variants that are often specific to cell type and/or developmental stage. The emerging genome-editing technology enables the creation of isogenic iPSCs and neurons to efficiently characterize the effects of SZ-associated regulatory variants on SZ-relevant molecular and cellular phenotypes involving dopaminergic, glutamatergic, and GABAergic neurotransmissions. SZ GWAS findings equipped with the emerging functional genomics approaches provide an unprecedented opportunity for understanding new disease biology and identifying novel drug targets.
    Neuroscience Bulletin 01/2015; 31(1). DOI:10.1007/s12264-014-1488-2 · 1.83 Impact Factor